{"filings":[{"id":834598,"accession_number":"0001104659-26-070124","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-06-03T20:30:32+00:00","items":["5.02"],"status":"ready","headline":"Ocugen CAO Ramachandran resigns; CFO Johnson-Greene named principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramesh Ramachandran resigned as Chief Accounting Officer, effective May 29, 2026.","CFO Rita Johnson-Greene appointed as principal accounting officer, effective June 3, 2026.","No arrangements or understandings between Johnson-Greene and others for the appointment.","No family relationships or disclosable transactions involving Johnson-Greene under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443563,"accession_number":"0001104659-26-061241","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-05-14T20:31:51+00:00","items":["5.02","8.01"],"status":"ready","headline":"Ocugen CMO Huma Qamar departs; Mohamed Genead named acting interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Huma Qamar separated from Ocugen as Chief Medical Officer effective May 8, 2026.","Mohamed Genead, M.D., appointed Acting/Interim Chief Medical Officer effective May 8, 2026.","No reason for departure or transition details were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443524,"accession_number":"0001104659-26-061230","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-05-14T20:30:23+00:00","items":["2.03","1.01","3.02","7.01","9.01"],"status":"ready","headline":"Ocugen closes $130M of 6.75% convertible senior notes due 2034, net proceeds ~$112.6M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $130.0M aggregate principal of 6.75% Convertible Senior Notes due 2034, including full $15M over-allotment exercise.","Net proceeds ~$112.6M after discount and expenses; offering price was 90% of principal.","Used $32.7M to fully repay outstanding loan under Avenue Capital Group agreement plus prepayment fees.","Remaining net proceeds for general corporate purposes; cash runway extended into 2028.","CEO cites momentum to advance three late-stage programs targeting three BLA filings by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92480,"accession_number":"0001104659-26-057138","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","3.02","9.01"],"status":"ready","headline":"Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$115M aggregate principal of 6.75% Convertible Senior Notes due 2034 issued; net proceeds ~$99.5M.","~$32.7M used to fully repay and terminate the Avenue Loan Agreement; remaining for general corporate purposes.","Pro-forma cash, cash equivalents, and restricted cash estimated at $99.0M as of March 31, 2026.","Initial conversion price ~$2.68/share (45% premium to $1.85 close on May 4, 2026); conversion rate 372.7866 shares per $1,000.","Exchange cap of 67,629,947 shares until stockholder approval; max initial shares issuable 62,162,162."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92479,"accession_number":"0001104659-26-055411","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ocugen posts Q1 loss, details positive Phase 2 GA data, prices $115M notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $(0.06) per share for Q1 2026; cash, cash equivalents, and restricted cash of $32.2M as of March 31, 2026.","Phase 2 OCU410 trial for GA showed statistically significant 31% reduction in lesion growth at 12 months with optimal dose; 20% of patients showed no progression.","Enrollment completed for OCU400 Phase 3 RP trial (N=140) and OCU410ST Stargardt Phase 2/3 trial (N=63); BLA submissions targeted by 2027.","Priced $115M (up to $130M with over-allotment) of 6.75% Convertible Senior Notes due 2034 at 90% of par; conversion premium of 45% at $2.68/shr.","Net proceeds ~$99.5M; $32.7M to repay Avenue debt (12.5% interest); expected to extend cash runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92478,"accession_number":"0001104659-26-054866","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Ocugen plans $115M convertible notes offering; preliminary cash $32.2M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering of $115M convertible senior notes due 2034, with initial purchaser option for additional $15M.","Net proceeds used to repay ~$32.7M Avenue Capital loan plus accrued interest and fees; remainder for general corporate purposes.","Preliminary cash, cash equivalents, and restricted cash of ~$32.2M as of March 31, 2026, unaudited.","Notes are senior unsecured, convertible into cash, stock, or combination; interest rate and conversion rate TBD upon pricing.","OCU400 Phase 3 enrollment complete, rolling BLA expected Q3 2026; OCU410ST trial fully dosed; OCU200 Phase 1 enrollment complete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103339,"accession_number":"0001628280-26-021541","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ocugen furnishes investor presentation; no material new details available from filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Exhibit 99.1 presentation attached to 8-K but full content not provided in the filing excerpt.","Ocugen (OCGN) continues to highlight gene therapy pipeline; no financial or clinical updates disclosed.","Presentation posted on company website for investor use; no specific new events or numbers reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103338,"accession_number":"0001104659-26-033724","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ocugen reports 31% reduction in GA lesion growth at 12 months in Phase 2 OCU410 trial; plans Phase 3 in Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["31% reduction in GA lesion growth (medium dose) vs control at 12 months (p<0.05); 55% of treated patients had ≥30% lesion reduction.","No OCU410-related serious adverse events; no endophthalmitis, retinal detachment, or vasculitis reported.","27% slower rate of ellipsoid zone loss vs control, indicating photoreceptor preservation.","Phase 3 pivotal trial with up to 300 subjects, adaptive design >95% power, expected to start Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103337,"accession_number":"0001104659-26-032442","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocugen raises $15M via partial warrant exercise; cash runway extended to Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor exercised warrants for 10,000,000 shares of common stock on March 12, 2026, raising $15.0M gross proceeds.","Proceeds expected to extend Ocugen's cash runway into the first quarter of 2027.","Warrants were issued as part of a $20M registered direct offering closed in August 2025.","The exercise was a partial exercise of outstanding warrants; additional warrants remain exercisable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103336,"accession_number":"0001104659-26-023290","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen files Section 205 petition to validate share increase; hearing set for May 6, 2026","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Petition seeks validation of Charter Amendment increasing authorized common shares from 295M to 390M, approved at June 2024 annual meeting.","Putative class action challenged voting rights of Series C Preferred Stock used to approve amendment; plaintiff does not oppose petition.","Company filed Certificate of Correction to clarify Series C Preferred voting powers; hearing on petition set for May 6, 2026.","As of Jan 22, 2026, Ocugen had issued 33M shares in reliance on the amendment, all subject to validation.","If petition granted, stockholder action will be mooted; Delaware Chancery Court to decide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103335,"accession_number":"0001104659-26-023288","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen Q4 2025 net loss $0.06/share; OCU400 Phase 3 enrollment complete; cash $18.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fourth quarter 2025 net loss $0.06 per share (vs $0.05 Q4 2024); full year net loss $0.23 per share (vs $0.20).","Cash and restricted cash $18.9M at Dec 31, 2025 ($58.8M year-end 2024); January 2026 raised $22.5M via stock offering led by RTW Investments.","OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa completed enrollment (140 patients); topline data expected Q1 2027.","OCU410ST Phase 2/3 GARDian trial nearing enrollment completion; interim data Q3 2026; OCU410 Phase 2 showed 46% lesion growth reduction.","Exclusive Korean rights to OCU400 licensed to Kwangdong Pharmaceutical with upfront fees and milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103334,"accession_number":"0001104659-26-011765","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ocugen names Rita Johnson-Greene CFO; base $440k, equity grants of 1.25M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Rita Johnson-Greene as CFO effective Feb 9, 2026, upon filing of FY2025 10-K.","Base salary $440,000, sign-on bonus $90,000, target annual bonus up to 45% of base.","Granted options for 750,000 shares and RSUs for 500,000 shares, vesting over three years.","Ramesh Ramachandran steps down as principal financial officer, remains CAO and principal accounting officer.","Severance: 12 months base pay continuation, COBRA; enhanced severance on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103333,"accession_number":"0001104659-26-006031","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ocugen closes $22.5M offering; net $20.85M extends cash runway into Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["15M shares sold at $1.50/share in underwritten registered direct offering.","Net proceeds of $20.85M after commissions and expenses.","RTW Investments led the offering; Oppenheimer & Co. sole bookrunner.","Proceeds expected to fund operations into Q4 2026 (previously disclosed earlier runway).","Use of proceeds: general corporate, working capital, capital expenditures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103332,"accession_number":"0001104659-26-005454","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ocugen prices $22.5M common stock offering at $1.50/share; led by RTW Investments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 15M shares of common stock at $1.50/share for gross proceeds of $22.5M; net proceeds ~$20.8M.","Offering led by RTW Investments with participation from new and existing investors; expected to close Jan 22, 2026.","Proceeds to be used for general corporate purposes, capital expenditures, working capital, and G&A.","Oppenheimer & Co. acting as sole book-running manager for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103331,"accession_number":"0001104659-26-003900","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen: OCU410 shows 46% GA lesion reduction in Phase 2; Phase 1 EZ loss 60% slower","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 preliminary 12-month data (N=23) shows 46% GA lesion growth reduction vs control (p=0.015); medium dose 54% (p=0.02), high dose 36% (p=0.05).","Subgroup with baseline ≥7.5 mm² (N=14) demonstrated 57% reduction in lesion size vs control.","Phase 1 (N=7 evaluable) shows 60% slower ellipsoid zone loss in treated eyes vs untreated fellow eyes at 12 months.","No OCU410-related serious adverse events reported across Phase 1 and Phase 2; no endophthalmitis, retinal detachment, or vasculitis.","Company plans full Phase 2 data later Q1 2026, initiate Phase 3 in 2026, and BLA filing in 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119581,"accession_number":"0001104659-25-122610","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocugen grants CEO Shankar Musunuri 9.37M performance-based RSUs tied to regulatory and stock milestones","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Award of 9,369,604 PSUs approved Dec 12, 2025; grant date Jan 2, 2026, in addition to regular annual grant.","Three-year performance period ending Dec 31, 2028; vesting upon Compensation Committee certification of milestone achievement.","Two-thirds of PSUs vest on regulatory milestones; one-third vests on stock performance milestone.","Unearned PSUs forfeited if milestones not achieved by end of Performance Period or upon CEO's termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119580,"accession_number":"0001104659-25-106664","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen Q3 net loss $20M; OCU400 Phase 3 nearing completion, Kwangdong deal signed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.0M ($0.07/sh) vs $13.0M ($0.05) in Q3 2024; cash $32.9M as of Sep 30 (down from $58.8M Dec 31).","OCU400 Phase 3 enrollment nearing completion; BLA filing target 1H 2026, top-line data expected 4Q 2026.","OCU410ST Phase 2/3 trial 50% enrolled; CHMP accepts single US trial for MAA; interim data mid-2026.","Signed licensing deal with Kwangdong for OCU400 in South Korea; up to $7.5M milestones plus sales milestones and 25% royalties.","Closed $20M registered direct offering; cash runway into Q2 2026; warrants exercise could add $30M and extend to 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4606000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136153,"accession_number":"0001104659-25-091097","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Ocugen-Carisma merger terminated after Ocugen failed to secure $25M investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Carisma terminated Merger Agreement on Sep 16, 2025 because Ocugen obtained less than $25M in commitments for the Concurrent Investment.","Ocugen attributes difficulty to poor market conditions and the tight timeline before Carisma's Nasdaq compliance deadline of Oct 7, 2025.","Ocugen will focus on gene therapies and continue exploring other options for its regenerative cell therapy platform, including NeoCart."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136152,"accession_number":"0001104659-25-090113","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Ocugen licenses OCU400 gene therapy to Kwangdong for South Korea; $1M upfront, up to $6.5M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license to Kwangdong for OCU400 (retinitis pigmentosa gene therapy) in South Korea.","$1M upfront; up to $6.5M in regulatory/development milestones plus sales milestones of $1.5M per $15M sales.","Royalty of 25% on net sales; Ocugen to manufacture commercial supply under separate agreement.","Term continues until 20 years after first commercial sale or last valid patent/exclusivity expiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136151,"accession_number":"0001104659-25-087801","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Ocugen signs subscription agreement to invest $5M in Carisma as part of Merger concurrent financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ocugen committed to purchase $5.0M of Carisma common stock at a price per share determined by formula per Merger Agreement.","Investment is part of a Concurrent Investment targeting aggregate gross proceeds of at least $25M from multiple investors.","Subscription Agreement includes MFN clause: if other investors get better terms, Ocugen automatically receives them.","Closing expected at or immediately after Merger closing, subject to customary conditions.","Carisma intends to enter Registration Rights Agreement with Investors, including Ocugen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136150,"accession_number":"0001104659-25-075956","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ocugen announces $20M registered direct offering of 20M shares + warrants to Janus Henderson","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $20M from 20M shares at $1.00 per share (Aug 7 close); warrants to buy 20M shares at $1.50, expiring 2 years.","Warrants callable by company if VWAP exceeds $2.50 for 5 of 30 consecutive trading days.","Investor is Janus Henderson; sole placement agent Noble Capital Markets receives 5.5% cash fee.","Investor agrees to 90-day lock-up on shares and warrant shares from closing.","Offering expected to close on or about August 11, 2025; up to $30M additional proceeds if warrants fully exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136149,"accession_number":"0001104659-25-072992","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen reports Q2 2025 results; cash $27.3M; initiates OCU410ST Phase 2/3 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and restricted cash $27.3M as of June 30, 2025, down from $58.8M at Dec 31, 2024; cash runway into Q1 2026.","Net loss $0.05 per share for Q2 2025, compared to $0.06 per share in Q2 2024; total operating expenses $15.2M.","Initiated dosing in Phase 2/3 GARDian3 trial for OCU410ST (Stargardt disease) after FDA clearance; received Rare Pediatric Disease Designation.","Signed binding term sheet for exclusive Korean rights to OCU400 with up to $11M in upfront and milestone payments.","Announced planned reverse merger of OrthoCellix with Carisma to spin off NeoCart, with OrthoCellix valued at $135M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2854000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136148,"accession_number":"0001104659-25-072197","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocugen wins dismissal with prejudice of securities class action lawsuit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Eastern District of Pennsylvania granted dismissal with prejudice on July 29, 2025.","Case No. 2:24-cv-01500; plaintiffs have 30 days to file an appeal.","Company states lawsuit is without merit and will vigorously defend if appealed.","Previously disclosed securities class action against Ocugen and certain agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136147,"accession_number":"0001104659-25-071374","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocugen regains Nasdaq minimum bid price compliance; deficiency matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on July 28, 2025 that closing bid price met $1.00 minimum for ten consecutive business days July 8–25, 2025.","Previously received deficiency notice on Dec 31, 2024 and was granted extension through Dec 29, 2025.","Compliance achieved earlier than extension deadline; matter now closed by Nasdaq.","Common stock ticker OCGN continues trading on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136146,"accession_number":"0001104659-25-064695","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocugen receives Nasdaq extension to Dec 29, 2025 to meet $1 bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ocugen granted 180-day extension until Dec 29, 2025 to regain compliance with Nasdaq minimum bid price $1.00.","Previously, on Dec 31, 2024, Nasdaq warned that stock had traded below $1 for 30 consecutive business days.","If bid price closes at $1.00 or more for 10 consecutive business days before Dec 29, compliance will be achieved.","Failure to demonstrate compliance by Dec 29 may result in delisting, subject to possible appeal to Nasdaq Hearing Panel.","No assurance that appeal would succeed if delisting is determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153220,"accession_number":"0001104659-25-061435","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ocugen's OrthoCellix to merge with Carisma in reverse merger; combined entity to focus on NeoCart","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OrthoCellix valued at $135M; Carisma at $15M; post-merger Ocugen/investors own ~90%, Carisma holders ~10%.","Concurrent $25M financing from Ocugen ($5M guaranteed) and other investors to fund NeoCart Phase 3 trial.","Combined company to trade as 'OrthoCellix Inc.' on Nasdaq under ticker OCLX; closing expected H2 2025.","NeoCart is Phase 3-ready autologous cartilage implant for knee defects; received FDA RMAT designation.","Carisma legacy asset CVRs issued to pre-merger Carisma stockholders; termination fees of $500K-$750K if deal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153219,"accession_number":"0001372299-25-000004","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen presents clinical data with significant LLVA improvement (p=0.005) at Year 1 in retinal disease study","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Mean change in LLVA from baseline improved in treated eye vs untreated (p=0.005 at Year 1).","75% of patients met responder criterion (6/8) at measured timepoints.","Mean total atrophy area change at Month 12 showed trend favoring treated eye (p=0.055).","Mean BCVA (ETDRS) change from baseline reported up to Month 12.","Presentation includes Year 1 and Year 2 data from the clinical trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153218,"accession_number":"0001104659-25-056875","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Ocugen signs binding term sheet to license OCU400 gene therapy in Korea; up to $11M upfront & milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront license fees and near-term development milestones up to $11M.","Sales milestones of $1M per $15M net sales in Korea (or $150M+ in first 10 years).","Royalty of 25% on net sales; Ocugen to manufacture and supply OCU400.","Estimated 15,000 RP patients in Korea; definitive agreement expected within 60 days.","OCU400 in Phase 3 with target BLA filing mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153217,"accession_number":"0001628280-25-024095","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen Q1 2025 net loss $0.05/sh; cash $38.1M; OCU400 Phase 3 on track for mid-2026 BLA/MAA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & restricted cash $38.1M as of Mar 31, 2025, down from $58.8M at Dec 31, 2024; runway into Q1 2026.","Operating expenses $16.0M (R&D $9.5M, G&A $6.5M) vs $13.2M in Q1 2024; net loss per share unchanged at $0.05.","OCU400 Phase 3 liMeliGhT RP trial recruiting; BLA/MAA filings targeted by mid-2026; ATMP classification from EMA.","OCU410ST Phase 2/3 pivotal trial for Stargardt disease to start mid-2025; BLA filing target 2027.","OCU410 for GA: Phase 2 dosing complete; 12-month data shows 4-line VA gain and 41% slower lesion growth."],"consensus_eps_estimate":-0.0525,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1481000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153216,"accession_number":"0001628280-25-021359","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ocugen presents clinical trial data at Eyecelerator conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation furnished as Exhibit 99.1; used at May 2, 2025 Eyecelerator showcase.","Data shows mean change in BCVA and visual field responder proportions.","Specific numerical results not fully extractable due to formatting in filing text.","No new financial results, guidance, or corporate updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153215,"accession_number":"0001104659-25-039478","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocugen board to replace Drs. Fernandes and Whittington at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Prabha Fernandes, Ph.D., resigns; Marna C. Whittington, Ph.D., will not stand for re-election.","Both departures effective at Ocugen's 2025 Annual Meeting of Stockholders.","Board nominates Satish Chandran, Ph.D. (CEO, Prodigy Biotech) and Blaise Coleman (former CEO, Endo) to fill the vacancies.","Dr. Chandran has prior roles as CEO at Somahlution, CTO at Pfizer Biotherapeutics; Mr. Coleman brings 20+ years pharma finance/ops experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153214,"accession_number":"0001628280-25-016700","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen posts investor presentation on website April 4, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation titled 'COPHY Presentation' posted for use with investors and analysts.","Exhibit text appears garbled; no specific data or claims extractable.","No forward-looking guidance or financial metrics disclosed in available text.","Filing does not indicate any change in business operations or corporate events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171994,"accession_number":"0001628280-25-010245","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen FY2024 net loss $0.20; advances three gene therapy programs toward BLA filings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $0.05/share; full-year net loss $0.20/share vs $0.26 in 2023.","Cash $58.8M as of Dec 31, 2024; runway into Q1 2026; $65M financing secured in H2 2024.","OCU400 Phase 3 RP enrollment on track for H1 2025; BLA/MAA target mid-2026.","OCU410ST Stargardt Phase 2/3 pivotal trial FDA-aligned; BLA target 2027.","OCU410 GA completed Phase 2 dosing; no serious adverse events; BLA target 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171993,"accession_number":"0001628280-25-009243","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen posts corporate presentation with clinical data; 6-month treated/untreated rates shown","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation shows 52% vs 44% for treated and untreated eyes at 6-month timeline.","Data likely from OCU400 gene therapy program for retinitis pigmentosa.","Presentation posted on company website March 3, 2025; used for investor discussions.","No formal guidance or regulatory update provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171992,"accession_number":"0001628280-25-005030","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen posts clinical presentation showing 84% reduction in mean total atrophy area in treated group","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reports mean change in total atrophy area from baseline: 0.12±0.36 mm² (treated) vs 0.73±0.26 mm² (untreated), an 84% difference.","A 44% efficacy metric also cited; specific endpoint not fully legible from exhibit.","Presentation posted on website and may be used in investor discussions; no formal press release or guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171989,"accession_number":"0001104659-25-010531","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K/A","filed_at":"2025-02-07T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Ocugen enters $30M term loan facility with Avenue Capital; issues 1.06M shares to lenders","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loans of $30M from Avenue Capital at prime + 4.25% (prime floor at closing), maturing Nov 1, 2028.","Proceeds for working capital; prepayment premiums range 3.0% to 0.5% depending on timing.","Lenders can convert up to $6M of principal into common stock at 80% of trading price, capped at 19.9% of outstanding shares.","Company issued 211,268 shares to Avenue 1 and 845,070 shares to Avenue 2 as equity kicker.","Collateral includes all assets with negative pledge on intellectual property; customary covenants and default provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171991,"accession_number":"0001628280-25-002925","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen posts corporate presentation showing positive retinal gene therapy data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Mean change in total atrophy area: treated 0.12±0.36 mm2 vs untreated 0.73±0.26 mm2 (84% less progression).","LL VA decline at 6 months was lower in treated eyes compared to untreated across multiple study cohorts.","Presentation features data from cohorts 006-001, 007-001, and 006-004 suggesting consistent treatment benefit.","Ocugen plans to use this presentation in discussions with investors and analysts on January 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171990,"accession_number":"0001104659-25-000827","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ocugen receives Nasdaq bid price deficiency notice; has until June 30, 2025 to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ocugen on Dec 31, 2024, that its stock closed below $1.00 for 30 consecutive business days.","Ocugen has 180 days, until June 30, 2025, to regain compliance by meeting $1.00 closing bid for 10 consecutive days.","If not cured by June 30, 2025, Ocugen may qualify for a second 180-day period if it meets certain conditions.","Ocugen intends to monitor the bid price and consider options but cannot assure compliance will be regained.","The notice does not immediately affect listing or trading on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188986,"accession_number":"0001628280-24-049669","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen releases presentation with clinical data showing treatment benefit in retinal disease studies","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation shows mean change in total atrophy area from baseline reduced by 84% in treated group (0.12 mm²) vs untreated (0.73 mm²).","Visual acuity improvement in treated eyes across multiple cohorts (006-001, 007-001, 006-004) compared to untreated.","Treated mutant group shows better outcomes than untreated mutant in LL VA change over 6 months.","Presentation posted on company website December 3, 2024 and may be used in investor discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188985,"accession_number":"0001104659-24-119698","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocugen appoints Ramesh Ramachandran as principal financial officer and principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Nov 14, 2024, Ramesh Ramachandran appointed principal financial officer and principal accounting officer.","Michael Breininger, Corporate Controller, ceases to serve in those roles as of the same date.","Ramachandran joined Ocugen in Sept 2024 as CAO; prior VP Finance & Corporate Controller at Tecomet.","He holds a CPA, CMA (US) and CPA (Canada); MBA from Jadavpur University.","No arrangements or family relationships disclosed in connection with the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188984,"accession_number":"0001628280-24-046920","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ocugen presents positive OCU400 clinical data: 84% less atrophy area in treated vs untreated","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["OCU400 (AAV encoding NR2E3) shows restoration of phototransduction genes and improved retinal structure in multiple RP/LCA models.","Mean change in total atrophy area from baseline: +0.12 mm² treated vs +0.73 mm² untreated (84% improvement).","LL VA change from baseline: treated patients improved while untreated declined over 12 months.","Preclinical ERG and histology data show slowed degeneration across five animal models (Rho-/-, RhoP23H+/-, Rd7, Rd1, Rd16)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188983,"accession_number":"0001628280-24-046583","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen Q3 2024 cash $39M; extends runway into 1Q2026 on $65M in financings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and restricted cash $39.0M as of Sept 30, 2024, vs $39.5M at Dec 31, 2023.","Closed $30M debt and $35M equity financings in Q3, extending cash runway into 1Q2026.","Total operating expenses $14.4M (R&D $8.1M, G&A $6.3M) vs $16.1M in Q3 2023.","OCU400 Phase 3 liMeliGhT trial for RP on track to complete enrollment in 1H2025.","OCU410 Phase 2 recruiting; OCU410ST DSMB approved Phase 2; OCU200 IND cleared for Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3291000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188982,"accession_number":"0001104659-24-115900","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Ocugen closes $30M credit facility with Avenue Capital; proceeds for clinical development","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loans of $30M fully funded on Nov 6, 2024; maturity Nov 1, 2028; interest rate prime + 4.25% (floor at closing prime).","Up to $6M of principal convertible into common stock at 80% of trading price; conversion capped at 19.9% of outstanding shares.","Issued 1,056,338 shares to Lenders under Subscription Agreement; registration statement to be filed within 90 days.","Proceeds to support OCU400 Phase 3 liMeliGhT trial and BLA/MAA submissions; cash runway extends into Q1 2026.","Loan secured by all assets; negative pledge on IP; prepayment premiums from 3% down to 0.5% over time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205464,"accession_number":"0001104659-24-088678","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen posts corporate presentation on website; no new material financial or operational details","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation covers gene and cell therapies and vaccines pipeline; no specific data disclosed.","No financial results, guidance, or business updates provided in the filing.","Presentation slide shows only a cover page with general mission statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205463,"accession_number":"0001628280-24-035974","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocugen reports Q2 net loss $0.04/sh; advances OCU400 Phase 3 trial, raises $32.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.04 in Q2 2024 versus $0.10 in Q2 2023; total operating expenses $16.6M, down from $24.0M.","Cash, equivalents, restricted cash $16.0M at June 30, 2024, down from $39.5M at Dec 31, 2023.","Subsequent to quarter end, closed public offering with net proceeds $32.6M, extending cash runway into Q3 2025.","Actively dosing patients in OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa; FDA approved expanded access program.","OCU410 Phase 2 initiated for geographic atrophy; OCU410ST high-dose dosing; OCU200 clinical hold discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":2155000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205462,"accession_number":"0001104659-24-085603","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ocugen gets FDA nod to begin expanded access program for OCU400 in retinitis pigmentosa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved expanded access program for OCU400 for adult RP patients 18+ with minimal retinal preservation.","OCU400 is a modifier gene therapy; positive Phase 1/2 data and ongoing Phase 3 liMeliGhT trial.","RP affects ~300,000 in US/Europe, 1.6M globally; EAP provides access before BLA approval.","Targets BLA and MAA approval in 2026; OCU400 has orphan drug and RMAT designations from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205461,"accession_number":"0001104659-24-084689","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ocugen prices $35M public offering of 30.4M shares at $1.15 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $35M; net proceeds expected ~$32.6M after underwriting discounts.","Underwriter granted 30-day option to purchase up to 4,565,217 additional shares at same price.","Proceeds to be used for general corporate purposes, working capital, and G&A expenses.","Offering expected to close on or about August 2, 2024; Titan Partners Group sole book-runner.","Financing led by a premier mutual fund with participation from leading life sciences investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205460,"accession_number":"0001104659-24-078321","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ocugen appoints PwC as new auditor effective after Q2 2024 filing, replacing EY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board appointed PwC as auditor for FY2024; EY will cease after Q2 2024 10-Q filing.","EY declined to participate in RFP and stand for re-election; no disagreement with Company.","No prior consultations with PwC on accounting principles or disagreements in past two years.","EY provided letter (Exhibit 16.1) agreeing with statements in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222387,"accession_number":"0001104659-24-076278","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ocugen shareholders approve increase in authorized common stock; two Class I directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shankar Musunuri and Junge Zhang elected as Class I directors with 55.8M and 54.5M votes for.","Proposal to ratify Ernst & Young as independent auditor was withdrawn by the company.","Increase in authorized common stock approved: ~80.5B for, ~25.5B against.","Charter amendments to limit officer liability and adjust voting requirements not approved.","Advisory vote on executive compensation and adjournment proposal both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222386,"accession_number":"0001104659-24-069112","cik":1372299,"company_name":"Ocugen, Inc.","ticker":"OCGN","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ocugen's auditor EY declines re-election for FY2024; company begins search for new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY notified Ocugen on May 31, 2024 it will not stand for re-election as auditor for fiscal year 2024, ceasing after filing Q2 2024 10-Q.","EY's 2023 and 2022 audit reports included going-concern explanatory paragraph; 2023 report also noted restatement of 2022 financials.","No disagreements between Ocugen and EY on accounting principles; EY identified material weakness in internal control over collaborative arrangements.","Ocugen initiated an RFP process with multiple firms including EY; EY declined to participate; new auditor not yet selected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":480701025.97101444,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-06T23:59:59+00:00|222386"}